In the CANDOR trial, among the prespecified subgroups, no significant differences were observed between the treatment groups; however, patients aged ≥75 years showed a trend of improvement in GHS/QOL scores in the Kd (mean difference 3.97) [ 101 ].
2
—
—
The sentences
Notably, in the subgroup analyses based on age and ECOG-PS, an increasing trend in the improvement of HRQOL was observed for all subgroups in terms of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) Global health status (GHS), physical functioning, pain, and fatigue scores.